News & Media

TELIX PHARMACEUTICALS AND ANMI PARTNER FOR PROSTATE CANCER IMAGING

Telix Pharmaceuticals (Telix) is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA (ANMI).

Melbourne, Australia, and LIÈGE, Belgium, Oct. 24, 2017

Telix Pharmaceuticals (Telix) is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA (ANMI).

To read the full release click here.